Scotia off on BMJ article

Shares of Scotia (LSE:SOH) lost 41p (27 percent) to 113.5p on Friday after the British Medical Journal reported that the company's Foscan photodynamic therapy to treat head and neck cancer caused partial thickness burns in 14 patients after minimal exposure to light. But according to Chris Blackwell, SOH's director of drug development, the BMJ article took a 14-patient subset out of the context of the 800 patients treated with Foscan. SOH filed an MAA for European approval and an NDA for U.S. approval in October 1999 (see BioCentury Oct. 11, 1999). Data on the 14 patients are included in the regulatory packages. ...